- AbbVie, Genmab, and Sarah Cannon Research Institute announced the joint development of Epkinly for DLBCL treatment.
- AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
AbbVie
pharmaceutical company
-
Genmab
Danish healthcare company
-
Nxera Pharma
company in Tokyo, Japan
Nothing else this week.
Related events
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- Syndax Pharmaceuticals and AbbVie are competing in the healthcare and biopharma sector.
- AbbVie, AstraZeneca, and GSK are major players in global drug development, facing challenges in the drug class and pursuing licensing deals with Chinese biotechs.
- AbbVie and Novo Nordisk are high-profile pharmaceutical stocks serving over 45 million people worldwide, with Cor acting as a significant distribution partner.